• Return to Headlines

Downgrade Alert for Alnylam Pharmaceuticals (ALNY)

By James Quinn

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded from Outperform to Market Perform at Leerink today. The stock closed yesterday at $36.21 on volume of 16.7 million shares, above average daily volume of 836,000.

Alnylam Pharmaceuticals has overhead space with shares priced $36.21, or 75.1% below the average consensus analyst price target of $145.67. The stock should run into initial resistance at its 50-day moving average (MA) of $63.90 and subsequent resistance at its 200-day MA of $85.26.

Alnylam Pharmaceuticals share prices have moved between a 52-week high of $140.00 and a 52-week low of $49.96 and closed yesterday at -28% above that low price at $36.21 per share. Over the past week, the 200-day moving average (MA) has gone down 1.7% while the 50-day MA has remained constant.

Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company. The Company is developing technology that can specifically and potently silence disease-causing genes.

SmarTrend is monitoring the recent change of momentum in Alnylam Pharmaceuticals. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Alnylam Pharmaceuticals in search of a potential trend change.

Keywords: analyst upgrades/downgrades alnylam pharmaceuticals

Ticker(s): ALNY